MAM
MLYS icon

Mark Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Mark Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.92M Buy
+144,875
New +$4.25M 0.36% 29
2025
Q4 		– Sell
-19,465
Closed -$738K – 56
2025
Q3 		$738K Buy
+19,465
New +$421K 0.05% 53

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Mark Asset Management's MLYS Position: Q1 2026 in Review

Mark Asset Management opened a new position in Mineralys Therapeutics (MLYS) in Q1 2026: 144,875 shares worth $3.92M. The stake represents 0.36% of the portfolio and ranks #29 among its holdings. This is a return to the name: Mark Asset Management previously reported a position in MLYS as recently as Q3 2025.

Mark Asset Management first reported a position in MLYS in Q3 2025 and has held it in 2 quarters since. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Mark Asset Management held 144,875 shares of Mineralys Therapeutics worth $3.92M as of Q1 2026.
  • Mineralys Therapeutics was a new Mark Asset Management position in Q1 2026.
  • Mineralys Therapeutics made up 0.36% of Mark Asset Management's portfolio in Q1 2026, its #29 holding.
  • Mark Asset Management first reported a position in Mineralys Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Mark Asset Management's 13F filing for Q1 2026, filed 15 May 2026.